Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Debt Issuance
confidence 85%
filed 2026-07-02
Item 1.01
Cheniere entered into three material credit facility agreements on June 26, 2026: a Commitment Increase and Maturity Extension Agreement increasing its revolving credit facility by $500 million to $1.75 billion and extending maturity to August 1, 2031; a new $1.0 billion CCH Revolving Credit Agreement to refinance and support Corpus Christi liquefaction and pipeline operations; and a Second Amendment to the CCH Term Loan Facility Agreement extending the availability period for term loan disbursements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 1.01
Enanta Pharmaceuticals entered into an Open Market Sale Agreement with Jefferies LLC authorizing the sale of up to $75 million in common stock through an at-the-market (ATM) offering. This is a dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a significant capital-raising event for the company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-02
Item 1.02
The filing discloses termination of a material lease for the Company's Genetic Medicines Manufacturing Center (GMMC Facility), with associated costs of $1.75 million in forfeited security deposit plus $294,200 termination fee. While Item 1.02 typically covers termination of material definitive agreements, this is fundamentally an operational restructuring decision—the Company decommissioned the facility in 2025 to reduce costs and is outsourcing manufacturing to a contract manufacturer. The event is material to investors as it reflects a strategic shift in manufacturing operations and carries quantifiable financial consequences, but does not fit the specific categories of workforce_reduction, ma_activity, or financial_other as precisely as operational_other.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-02
Item 1.01
LivePerson entered into an Amended and Restated Merger Agreement on July 2, 2026, with SoundHound AI, Inc. and its subsidiaries (Merger Subs) to effect a merger whereby LivePerson will become an indirect wholly owned subsidiary of SoundHound. This is a material acquisition/change of control transaction involving the issuance of SoundHound Common Stock to LivePerson stockholders (except TASE Shares, which will receive cash consideration). The filing explicitly discloses the merger structure, consideration amounts, and closing conditions, all hallmarks of a material M&A activity disclosure under Item 1.01.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-02
Item 5.02
Erin Chapple voluntarily resigned as a member of the Board of Directors effective June 30, 2026. The disclosure explicitly states her departure was not due to disagreement with the Company, and the Board subsequently approved a reduction in board size from 11 to 10 directors. This is a clear executive departure event involving a director leaving office.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-02
Item 1.01
Core & Main issued $750 million of 6.000% Senior Notes due 2034 on July 1, 2026, pursuant to a new indenture. This is a material creation of a direct financial obligation. The filing also discloses a Sixth Amendment to the Term Loan Credit Agreement refinancing the 2028 Senior Term Loan with a new $800 million 2033 Senior Term Loan. Both transactions constitute debt issuances under Item 1.01, with the Notes being the primary new obligation disclosed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-02
Item 8.01
The filing discloses receipt of an unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer's Chair and CEO, to acquire all outstanding shares of Class A common stock for $2.45 per share in cash plus two contingent value rights. This constitutes a material M&A activity event under Item 8.01, as it represents a potential change of control transaction that would materially affect the registrant and require board evaluation and stockholder consideration.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-02
EX-99.1
This is an ASX Appendix 2A application for quotation of 34,824 ordinary shares issued on vesting of 54,480 performance rights under an employee incentive scheme on 2–3 July 2026. While the immediate issuance is modest in absolute terms, it represents a dilutive equity event (conversion of unquoted performance rights into quoted ordinary shares) that increases the share count and would be material to a reasonable investor assessing capital structure and dilution. The document confirms the securities rank equally with existing ordinary shares and notes substantial unquoted convertible securities (45.2M convertible notes, 35M convertible debentures) that pose future dilution risk.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-07-02
Item 1.01
The Company entered into a Second Amendment to its Loan and Security Agreement, increasing the maximum facility amount from $250 million to $400 million (with accordion feature to $450 million), reducing the applicable margin, and extending key maturity dates. Additionally, total commitments under the SMBC Revolving Credit Facility were increased from $650 million to $675 million on June 30, 2026, representing material expansions of the Company's direct financial obligations and borrowing capacity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-02
Item 1.01
ITG, Inc. entered into material definitive agreements in connection with its initial public offering (IPO), including an Underwriting Agreement, Tax Receivable Agreement, Stockholders Agreement, and Registration Rights Agreement. The IPO represents a material change of control and capital event that significantly affects investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 8.01
ITG, Inc. completed an initial public offering on July 2, 2026, issuing 19,512,196 shares of Class A Common Stock at $16.00 per share, with underwriters exercising an option to purchase an additional 2,926,829 shares. The proceeds were used to purchase LLC interests from ITG Parent, which then repaid debt facilities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
ITG, Inc. issued over 101 million shares of Class A and Class B Common Stock to Oaktree Blocked Fund, Oaktree Aggregator, and ITG Management Holdings, LLC on July 1, 2026, in reliance on Section 4(a)(2) exemption from Securities Act registration as part of a restructuring or recapitalization transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
Francis A. Braun III and Dylan G. Petre were appointed to the Board of Directors effective July 1, 2026 upon listing, with Braun designated as Audit Committee chair and Petre appointed to the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-07-02
Item 3.03
ITG, Inc. modified security holder rights through a Registration Rights Agreement and related amendments, affecting shareholders' ability to liquidate holdings and other governance matters in connection with the IPO.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-02
Item 1.01
Arcturus entered into a material strategic collaboration with Thermo Fisher Scientific on June 26, 2026, comprising a Master Services Agreement and Project Addendum for CDMO and CRO services for ARCT-032 (cystic fibrosis therapy). The transaction includes up to $40 million in clinical manufacturing services and $40 million in CRO services, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-02
Polibeli Group entered into a non-binding memorandum of understanding with AUTHAIKAM COMPANY LIMITED on June 30, 2026, to evaluate a potential AI computing center opportunity in Thailand with planned power capacity of up to 100 MW. While the MOU is non-binding and the project remains at preliminary evaluation stage with no capital commitment yet, the disclosure of a strategic expansion into AI infrastructure in a new jurisdiction represents a material operational and strategic business development that would affect a reasonable investor's assessment of the company's growth trajectory and business direction.
View raw filing on EDGAR →
8-K
Governance Other
confidence 80%
filed 2026-07-02
Item 1.01
Vaxart entered into a Cooperation Agreement with a stockholder group that resolves a proxy contest through comprehensive governance enhancements, including the appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), adoption of director stock ownership and resignation policies, and quarterly management engagement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-02
EX-99.1
This press release announces a strategic repositioning of POMDOCTOR from a traditional online healthcare platform toward an AI-enabled predictive healthcare infrastructure provider. The announcement describes a significant business model evolution integrating wearable technologies, AI analytics, physician services, and healthcare payment networks. While this is a strategic business announcement rather than a discrete operational event (like a contract, partnership, or regulatory milestone), it represents a material shift in the company's strategic direction and business positioning that would affect a reasonable investor's assessment of the company's future prospects and competitive positioning.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-02
EX-99.1
Yiren Digital's board has authorized a new share repurchase program permitting the company to repurchase up to 10% of outstanding shares for up to $20 million over the next 12 months. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs." The $20 million authorization and 10% share cap represent a material capital allocation decision that would affect a reasonable investor's assessment of the company's capital strategy and shareholder returns.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-02
Item 1.01
CID Holdco entered into a Note Purchase Agreement on June 23, 2026, creating a new $500,000 Senior Secured Convertible Promissory Note with Phillips Equities & Trust, LLC, bearing 6% interest, 12-month maturity, convertibility into common stock, and secured by substantially all company assets.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-02
Item 1.02
CID Holdco retired in full approximately $867,000 principal of White Lion Senior Secured Convertible Promissory Notes through conversion and released all associated liens and security interests, simplifying the company's capital structure and eliminating secured debt obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
CID Holdco issued a $500,000 secured convertible note to a new investor in reliance on Section 4(a)(2) and Regulation D exemptions, providing additional capital through an unregistered private placement of a dilutive equity instrument.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-02
Item 8.01
CID Holdco disclosed ongoing Nasdaq continued listing compliance deficiencies regarding minimum market value of listed securities ($50 million) and minimum market value of publicly held shares ($15 million), despite regaining compliance with the Bid Price Requirement as of June 23, 2026.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-02
EX-99.1
Brenmiller Energy announced the purchase of a 1.2 MWp photovoltaic facility in Hungary for approximately $1.1 million. This is a material acquisition of a revenue-generating asset that marks a strategic shift in the company's business model—from a thermal energy storage equipment provider toward an owner and operator of clean energy infrastructure. The press release explicitly states this purchase "marks an important step in Brenmiller's evolution" and is "the first execution of Brenmiller Energy's BNRG360 strategy," indicating this is a significant strategic transaction that would affect a reasonable investor's assessment of the company's direction and asset base.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-02
Item 8.01
The filing discloses a significant business development: Virtuix's first Air National Guard deployment of its Omni One platform, along with a series of recent defense sector wins (Air Force SBIR award, Marine Corps lead integrator role, Navy development agreement, Army/Air Force deployments). The company also announces it is "actively reviewing several acquisition opportunities in the defense training and simulation sector" targeting companies with $10–50M in annual revenue. This is a material operational and strategic milestone expanding the company's defense market presence, though it does not fit the specific categories of M&A activity (no acquisition completed), earnings release, or other named event types. The disclosure would affect a reasonable investor's assessment of the company's growth trajectory and market positioning.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-02
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from the Annual Meeting of Stockholders held on July 1, 2026. The filing reports the final voting tallies for two proposals: (1) election of Class I directors Glenn Duffy and William Gates, and (2) ratification of Grant Thornton LLP as independent auditor. The disclosure of director elections and auditor ratification results is material to investors' understanding of corporate governance and board composition.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-02
The 6-K reports the results of Turbo Energy's Annual General Shareholders' Meeting held on June 29, 2026, disclosing voting outcomes on eight proposals including election of eight board directors (Proposal 1, approved 99.50%), ratification of auditors (Proposals 2 and 3), approval of annual accounts and management (Proposals 4–6), and procedural matters (Proposals 7–8). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material because board elections and auditor ratifications affect governance and investor assessment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-02
EX-99.1
This press release announces successful completion of biocompatibility testing for NASARIX, a development-stage medical device product. The disclosure describes achievement of a pre-clinical regulatory milestone—passing all required biological safety assessments under ISO 10993 standards—that supports advancement toward first-in-human clinical trials. While this is a material operational/development milestone for a biotech company, it does not fit the specific event categories (earnings, M&A, executive changes, impairment, etc.); it is a product development achievement that materially advances the company's clinical and regulatory pathway.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-07-02
Item 4.01
The filing discloses the dismissal of Simon & Edward, LLP as the independent registered public accounting firm and engagement of Kreit & Chiu CPA LLP as the new auditor, effective June 30, 2026. This is a direct auditor change under Item 4.01. While the prior auditor's reports were unqualified except for a going-concern explanatory paragraph and there were no disagreements, the change itself is material to investors as it affects the registrant's financial reporting oversight and audit continuity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-02
Item 1.01
Tenon Medical completed a registered public offering on July 1, 2026, issuing 11,052,631 shares of common stock (or pre-funded warrants) and 13,263,159 common stock purchase warrants, raising $4.2 million in gross proceeds. The offering includes warrants exercisable at $0.38 and $0.001 per share, with proceeds to be used in part for repayment of convertible notes, reflecting significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
ISQ Open Infrastructure Co LLC completed unregistered sales of equity securities totaling $31.9 million across Series I and Series II share classes as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-02
Item 8.01
The company acquired two equity investments in Mercury Data Center Holdings Limited and Cube Safety HoldCo Limited in June 2026, representing material portfolio expansion into data center and traffic safety infrastructure sectors.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-07-02
Item 8.01
This disclosure reports the consummation of Alpex Acquisition Corporation's initial public offering on June 26, 2026, raising $115 million in gross proceeds from the sale of 11.5 million units (including full exercise of the underwriter's over-allotment option) at $10.00 per unit, plus a concurrent private placement of 187,500 units to the sponsor for $1.875 million. While IPO completion is a material capital-raising event affecting the registrant's financial position and ability to pursue a business combination, it does not fit neatly into the standard 8-K taxonomy categories (which typically cover earnings releases, M&A activity, debt issuance, or other specific financial/operational events). The event is clearly material to investors but is best classified as a capital formation milestone that does not match a named category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 8.01
The Company sold 76.35 million shares of Common Stock over two days (June 30 and July 1, 2026) pursuant to an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners, raising approximately $7.11 million in gross proceeds. This represents a dilutive issuance that increased outstanding shares from 21.5 million to 97.9 million—a 355% increase—which is material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-02
EX-99.1
This press release announces the results of WISeKey's 2026 Annual General Meeting held on June 29, 2026, disclosing that shareholders approved all agenda items including re-election of directors, election of a new director (Andrew Forson), re-election of the Chairman (Carlos Moreira), approval of the 2025 Annual Report, and all compensation-related proposals. This is a direct disclosure of shareholder vote results, matching Item 5.07 of the 8-K taxonomy and the `shareholder_vote_results` event type.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
Item 3.01
HeartBeam received a deficiency notice from Nasdaq on June 30, 2026, for failure to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been given a 180-day compliance period (until December 28, 2026) to regain compliance, with the explicit warning that failure to do so will result in delisting notice. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-02
EX-99.1
MDxHealth received a Nasdaq notification dated June 30, 2026, that it has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until December 28, 2026) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-02
Bank of Chile placed senior dematerialized bearer bonds (Serie GA) in the local Chilean market on July 2, 2026, for CLF 250,000 with a maturity date of May 1, 2034, at an average placement rate of 3.03%. This is a creation of a new direct financial obligation and is explicitly filed as "Material Information" with the Chilean Financial Market Commission, meeting the definition of debt_issuance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-02
The 6-K discloses an amendment to a share purchase agreement for the acquisition of a 51% interest in RENTBUDDYUK LIMITED, with the transaction closing on June 29, 2026. The amendment restructures the acquisition mechanism (newly issued shares rather than existing share purchase) but maintains the material economic terms of US$5,326,840 total consideration. This constitutes a material acquisition activity requiring disclosure under Item 1.01 or 2.01 of the 8-K framework.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-02
Item 5.02
The company amended the Executive Employment Agreement of CEO Eric Gripentrog, replacing a $500,000 performance equity award with a grant of 3,500,000 fully vested stock options at $0.0055 per share. The amendment was approved by the Compensation Committee on June 30, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-02
Item 1.01
Columbus Circle Capital Corp II (Inflection Point), a SPAC, entered into a Business Combination Agreement dated June 26, 2026, with Elroy Air, Inc., whereby Inflection Point's merger subsidiary will merge with Elroy Air with Elroy Air as the surviving corporation. The transaction involves an $800 million purchase price, conversion of Elroy Air securities, and a $66.6 million pre-funded convertible note investment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
Elroy Air issued unregistered convertible promissory notes and warrants to institutional investors in a pre-funded offering under Section 4(a)(2) of the Securities Act as part of the business combination transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Michael Blitzer was appointed as director and Chairman of the Board, and Kevin Shannon was appointed as Chief Executive Officer, both effective June 26, 2026, in connection with the Business Combination Agreement with Inflection Point Asset Management LLC.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-02
Item 1.01
OS Therapies entered into a securities purchase agreement on June 30, 2026, to issue a $10 million senior secured convertible promissory note, 275,000 commitment shares, and a five-year warrant for 1,750,000 shares to Leonite Fund I, LP in a private placement. The transaction includes anti-dilution provisions and beneficial ownership limitations tied to NYSE American stockholder-approval thresholds, with the company obligated to seek stockholder approval within 90 days.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-02
Item 2.03
OS Therapies established a $10 million line of credit supported by its UK subsidiary's tax credits, with an initial draw of $1.6 million, creating a new direct financial obligation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 83%
filed 2026-07-02
Item 5.02
Dr. Craig Eagle was appointed to OS Therapies' Board of Directors effective June 1, 2026, transitioning from Chief Medical Advisor. Dr. Eagle brings substantial oncology and pharmaceutical leadership experience, including prior roles as CMO at Guardant Health, VP Medical Affairs at Genentech, and senior positions at Pfizer.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-02
Item 5.02
The Compensation Committee approved a waiver to Section 3.2 of Bryant Riley's Employment Agreement, releasing holdback amounts attributable to Q1 and Q2 2026 that would otherwise have been withheld until Q1 2027. This is a modification of compensatory arrangements for a named executive officer, directly affecting the timing and amount of compensation payments. The waiver is material as it represents a material change to the executive's compensation structure based on performance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-02
The Company issued 2,400,000 Class B ordinary shares to the CEO/Chairman's affiliate (Lianyue Holding Limited) at $0.165 per share for gross proceeds of $396,000 under Regulation S. This is an unregistered equity issuance that is dilutive to existing shareholders; post-closing, the CEO's affiliate controls approximately 97.69% of aggregate voting power, representing a material concentration of control and significant dilution to public shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-02
The filing discloses two material events: (1) completion of the Mortgage One Group acquisition (Item 2.01, ma_activity), and (2) a Nasdaq delisting notice due to failure to maintain the $1.00 minimum bid price for 30 consecutive business days (Item 3.01, delisting_risk). While both are material, the delisting notice is the more urgent and existential threat to the registrant. The company has 180 days to regain compliance or faces delisting, with explicit language that "there can be no assurance that the Company will be able to regain or maintain compliance." This is a terminal listing risk that would materially affect investor assessment.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-07-02
Item 4.01
The filing discloses the dismissal of PwC (Kesselman & Kesselman) as the Company's independent registered public accounting firm effective July 1, 2026, and the simultaneous engagement of Barzily & Co. as the new auditor. This is a classic auditor change under Item 4.01. The materiality is heightened by the fact that PwC's prior audit reports included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern, signaling underlying financial stress that makes the auditor transition material to investors.
View raw filing on EDGAR →